Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes | Arteriosclerosis, Thrombosis, and Vascular Biology
JCI Insight - Dual PPARα/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction
Molecules | Free Full-Text | Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease
IJMS | Free Full-Text | PPAR Agonists and Metabolic Syndrome: An Established Role?
![PDF] A clinical update on peroxisome proliferator-activated receptors | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8d9fd09e39613346f83fc51709f77ecd8d56c850/2-Table1-1.png "PDF] A clinical update on peroxisome proliferator-activated receptors | Semantic Scholar")
PDF] A clinical update on peroxisome proliferator-activated receptors | Semantic Scholar
PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? | International Journal of Obesity
PPAR-α and PPAR-γ agonists for type 2 diabetes - The Lancet
Glitazones Activate PGC-1α Signaling via PPAR-γ: A Promising Strategy for Antiparkinsonism Therapeutics | ACS Chemical Neuroscience
Mechanism by which of PPAR γ ligands regulate insulin sensitivity. In... | Download Scientific Diagram
Dual PPARα + PPARγ agonists (glitazars) | Download Scientific Diagram
Frontiers | PPAR-γ Modulators as Current and Potential Cancer Treatments
The therapeutic potential of inhibiting PPARγ phosphorylation to treat type 2 diabetes - ScienceDirect
Endocrinologic and Metabolic Drugs Peroxisome Proliferator-Activated Receptor (PPAR) Agonists Preclinical and Clinical Cardiac Safety Considerations Jeri. - ppt download
The Many Faces of PPARγ: Cell
Frontiers | The Protective Effects of Peroxisome Proliferator-Activated Receptor Gamma in Cerebral Ischemia-Reperfusion Injury
Frontiers | The Role of Peroxisome Proliferator-Activated Receptor Gamma and Atherosclerosis: Post-translational Modification and Selective Modulators
Inhibition of PPARγ by Natural Compounds as a Promising Strategy in Obesity and Diabetes
Peroxisome proliferator‐activated receptor‐γ: too much of a good thing causes harm | EMBO reports
PDB-101: Global Health: Diabetes Mellitus: Drugs: Thiazolidinedione: PPAR-γ
PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? | International Journal of Obesity
Peroxisom-Proliferator-aktivierte Rezeptoren – Wikipedia
Interactions between PPAR Gamma and the Canonical Wnt/Beta-Catenin Pathway in Type 2 Diabetes and Colon Cancer
